MX2019000043A - Antagonistas de integrina de tetrahidronaftiridinpentanamida. - Google Patents
Antagonistas de integrina de tetrahidronaftiridinpentanamida.Info
- Publication number
- MX2019000043A MX2019000043A MX2019000043A MX2019000043A MX2019000043A MX 2019000043 A MX2019000043 A MX 2019000043A MX 2019000043 A MX2019000043 A MX 2019000043A MX 2019000043 A MX2019000043 A MX 2019000043A MX 2019000043 A MX2019000043 A MX 2019000043A
- Authority
- MX
- Mexico
- Prior art keywords
- avß3
- tetrahydronaphthyridinepentanamide
- disease
- integrin antagonists
- tanamido
- Prior art date
Links
- MUCAYJCKFRQNOH-UHFFFAOYSA-N 5-(1,2,3,4-tetrahydro-1,8-naphthyridin-2-yl)pentanamide Chemical compound N1C(CCC2=CC=CN=C12)CCCCC(=O)N MUCAYJCKFRQNOH-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 102100033167 Elastin Human genes 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000009889 Herpes Simplex Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038910 Retinitis Diseases 0.000 abstract 1
- 208000002220 Supravalvular aortic stenosis Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 206010049644 Williams syndrome Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 150000004652 butanoic acids Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662358330P | 2016-07-05 | 2016-07-05 | |
| US201662374234P | 2016-08-12 | 2016-08-12 | |
| PCT/US2017/040657 WO2018009501A1 (en) | 2016-07-05 | 2017-07-05 | Tetrahydronaphthyridinepentanamide integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000043A true MX2019000043A (es) | 2019-07-04 |
Family
ID=60912284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000043A MX2019000043A (es) | 2016-07-05 | 2017-07-05 | Antagonistas de integrina de tetrahidronaftiridinpentanamida. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11192889B2 (https=) |
| EP (1) | EP3481814B1 (https=) |
| JP (1) | JP2019524702A (https=) |
| KR (1) | KR20190026001A (https=) |
| CN (1) | CN109476632A (https=) |
| AU (1) | AU2017292754B2 (https=) |
| CA (1) | CA3029829A1 (https=) |
| MX (1) | MX2019000043A (https=) |
| WO (1) | WO2018009501A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE |
| MX394210B (es) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | INHIBIDORES DE INTEGRINA AVß6. |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| AU2019318538B2 (en) | 2018-08-08 | 2025-02-06 | The General Hospital Corporation | Polypeptide integrin antagonists |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (sl) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Zaviralci integrina alfa v beta6 |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN114173803A (zh) * | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| TW202329973A (zh) * | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
| WO2024125634A1 (zh) * | 2022-12-16 | 2024-06-20 | 西藏海思科制药有限公司 | 一种四氢萘啶类化合物及其在医药上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20010033248A (ko) * | 1997-12-17 | 2001-04-25 | 폴락 돈나 엘. | 인테그린 수용체 길항제 |
| CN1589145A (zh) * | 1999-06-02 | 2005-03-02 | 麦克公司 | αv整联蛋白受体拮抗剂 |
| FR2808798A1 (fr) | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| AU7793501A (en) * | 2000-07-26 | 2002-02-05 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| EP1389205B1 (en) * | 2001-04-09 | 2005-12-21 | Ortho-McNeil Pharmaceutical Research Inc. | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| JP2003277340A (ja) * | 2002-03-22 | 2003-10-02 | Toray Ind Inc | 接着分子阻害剤及び新規アミノ酸誘導体 |
| EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN |
| PT2953948T (pt) * | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
-
2017
- 2017-07-05 US US16/315,093 patent/US11192889B2/en active Active
- 2017-07-05 WO PCT/US2017/040657 patent/WO2018009501A1/en not_active Ceased
- 2017-07-05 EP EP17824775.5A patent/EP3481814B1/en not_active Not-in-force
- 2017-07-05 AU AU2017292754A patent/AU2017292754B2/en active Active
- 2017-07-05 KR KR1020197003579A patent/KR20190026001A/ko not_active Ceased
- 2017-07-05 CN CN201780042122.9A patent/CN109476632A/zh active Pending
- 2017-07-05 JP JP2019500301A patent/JP2019524702A/ja active Pending
- 2017-07-05 CA CA3029829A patent/CA3029829A1/en not_active Abandoned
- 2017-07-05 MX MX2019000043A patent/MX2019000043A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190026001A (ko) | 2019-03-12 |
| EP3481814A4 (en) | 2019-12-04 |
| EP3481814A1 (en) | 2019-05-15 |
| WO2018009501A1 (en) | 2018-01-11 |
| EP3481814B1 (en) | 2022-04-27 |
| CA3029829A1 (en) | 2018-01-11 |
| JP2019524702A (ja) | 2019-09-05 |
| AU2017292754A1 (en) | 2019-01-24 |
| AU2017292754B2 (en) | 2021-06-17 |
| US11192889B2 (en) | 2021-12-07 |
| CN109476632A (zh) | 2019-03-15 |
| US20200181138A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000043A (es) | Antagonistas de integrina de tetrahidronaftiridinpentanamida. | |
| USD780318S1 (en) | Pair of orthopedic arch supports | |
| IL287128B1 (en) | GLP-1R agonists, pharmaceutical compositions containing them and their uses in the treatment of cardiometabolic and related diseases | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| USD777325S1 (en) | Syringe tip | |
| AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| EP3536168A3 (en) | Probiotic formulations and methods for use | |
| WO2015138716A3 (en) | Anti-infective and osteogenic compositions and methods of use | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| WO2015143418A3 (en) | Gene therapy for retinitis pigmentosa | |
| MX2023014145A (es) | Oligonucleotidos modificados y metodos de uso. | |
| PH12017502216A1 (en) | Nucleic acid-cationic polymer compositions and methods of making and using the same | |
| MX2021014905A (es) | Células seguras e invisibles para el sistema inmunitario. | |
| PE20190381A1 (es) | Oligonucleotidos antisentido para modular la expresion de htra1 | |
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| WO2016014527A3 (en) | Stabilized nucleotides for medical treatment | |
| WO2018118819A3 (en) | Armed oncolytic viruses | |
| MX2019015676A (es) | Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento. | |
| WO2016130581A8 (en) | Combination cancer therapy | |
| MX2020007559A (es) | Formulaciones farmaceuticas. | |
| EP4403560A3 (en) | Macrocyclic compounds and uses thereof |